Biogen Takes Aim At Amgen’s Tavneos With Vanqua Licensing Pact

 
• By Joseph Haas
  
Biogen licenses preclinical asset from Vanqua that may compete with Amgen's Tavneos (Shutterstock)

More from Deals

More from Business